Khondrion Begins Phase II Trial of Sonlicromanol in Post-COVID Fatigue
NIJMEGEN, The Netherlands, May 19, 2026 Khondrion announced that the first patient has been dosed in the Phase II...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NIJMEGEN, The Netherlands, May 19, 2026 Khondrion announced that the first patient has been dosed in the Phase II...
NIJMEGEN, The Netherlands, April 16, 2026 Khondrion has announced a significant clinical milestone with the first patient dosed in...
